{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T08:56:20Z","timestamp":1793782580794,"version":"4.6.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:00:00Z","timestamp":1613088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Ovarian cancer (OC) is one of the most common gynecologic cancer, which has the worst prognosis and highest mortality rate. The lack of curative treatment and the high relapse rate, especially in advanced OC, continues to present a clinical challenge, highlighting the need for new therapeutic strategies. This study was performed to compare the expression of PD-L1 in primary epithelial ovarian cancer (EOC) and their corresponding peritoneal metastases, as well as to evaluate its correlation with clinico-pathological parameters. In total, 194 treatment na\u00efve paired EOC and peritoneal metastasis were analyzed by immunohistochemistry for PD-L1 expression. Clinico-pathological information was available for all patients. Significant differences in PD-L1 expression were found between primary EOC and peritoneal metastasis (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). We found discordant tumor cell PD-L1 expression between primary tumors and corresponding peritoneal metastasis in 34% (66\/194) of cases. Furthermore, PD-L1 expression in peritoneal metastasis samples was significantly associated with adverse prognostic factors, such as high proliferative index (Ki67) (<jats:italic>p<\/jats:italic>\u2009=\u20090.0039) and high histologic grade (<jats:italic>p<\/jats:italic>\u2009=\u20090.0330). In conclusion, the discordance of PD-L1 expression between primary EOC and corresponding peritoneal metastases suggests that its assessment as a potential biomarker for predicting response to anti-PD-L1 therapy may require analysis of metastatic lesions.<\/jats:p>","DOI":"10.1038\/s41598-021-83276-z","type":"journal-article","created":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T11:07:44Z","timestamp":1613128064000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Differential expression of PD-L1 between primary and metastatic epithelial ovarian cancer and its clinico-pathological correlation"],"prefix":"10.1038","volume":"11","author":[{"given":"Sandeep Kumar","family":"Parvathareddy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdul K.","family":"Siraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail A.","family":"Al-Badawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asma","family":"Tulbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fouad","family":"Al-Dayel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khawla S.","family":"Al-Kuraya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,12]]},"reference":[{"key":"83276_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394\u2013424 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"83276_CR2","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/annonc\/mdw306","volume":"27","author":"M Malvezzi","year":"2016","unstructured":"Malvezzi, M., Carioli, G., Rodriguez, T., Negri, E. & La Vecchia, C. Global trends and predictions in ovarian cancer mortality. Ann. Oncol. 27, 2017\u20132025 (2016).","journal-title":"Ann. Oncol."},{"key":"83276_CR3","doi-asserted-by":"crossref","first-page":"280","DOI":"10.3322\/caac.21559","volume":"69","author":"S Lheureux","year":"2019","unstructured":"Lheureux, S., Braunstein, M. & Oza, A. M. Epithelial ovarian cancer: evolution of management in the era of precision medicine. CA Cancer J. Clin. 69, 280\u2013304 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"83276_CR4","doi-asserted-by":"publisher","first-page":"284","DOI":"10.3322\/caac.21456","volume":"68","author":"LA Torre","year":"2018","unstructured":"Torre, L. A. et al. Ovarian cancer statistics, 2018. CA Cancer J. Clin. 68, 284\u2013296 (2018).","journal-title":"CA Cancer J. Clin."},{"key":"83276_CR5","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1158\/1078-0432.CCR-12-2199","volume":"19","author":"K Abiko","year":"2013","unstructured":"Abiko, K. et al. PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction. Clin. Cancer Res. 19, 1363\u20131374 (2013).","journal-title":"Clin. Cancer Res."},{"key":"83276_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrclinonc.2015.224","volume":"13","author":"S Narod","year":"2016","unstructured":"Narod, S. Can advanced-stage ovarian cancer be cured?. Nat. Rev. Clin. Oncol. 13, 255 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"83276_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21551","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2019. CA Cancer J. Clin. 69, 7\u201334 (2019).","journal-title":"CA Cancer J. Clin."},{"key":"83276_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-018-0191-1","volume":"50","author":"P Darvin","year":"2018","unstructured":"Darvin, P., Toor, S. M., Nair, V. S. & Elkord, E. Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp. Mol. Med. 50, 1\u201311 (2018).","journal-title":"Exp. Mol. Med."},{"key":"83276_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"83276_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","volume":"373","author":"J Brahmer","year":"2015","unstructured":"Brahmer, J. et al. Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer. N. Engl. J. Med. 373, 123\u2013135 (2015).","journal-title":"N. Engl. J. Med."},{"key":"83276_CR11","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian, S. L., Taube, J. M., Anders, R. A. & Pardoll, D. M. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat. Rev. Cancer 16, 275\u2013287 (2016).","journal-title":"Nat. Rev. Cancer"},{"key":"83276_CR12","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1093\/annonc\/mdv615","volume":"27","author":"J Chen","year":"2016","unstructured":"Chen, J., Jiang, C., Jin, L. & Zhang, X. Regulation of PD-L1: a novel role of pro-survival signalling in cancer. Ann. Oncol. 27, 409\u2013416 (2016).","journal-title":"Ann. Oncol."},{"key":"83276_CR13","doi-asserted-by":"publisher","first-page":"328rv324","DOI":"10.1126\/scitranslmed.aad7118","volume":"8","author":"W Zou","year":"2016","unstructured":"Zou, W., Wolchok, J. D. & Chen, L. PD-L1 (B7\u2013H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv324 (2016).","journal-title":"Sci. Transl. Med."},{"key":"83276_CR14","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455\u20132465 (2012).","journal-title":"N. Engl. J. Med."},{"key":"83276_CR15","doi-asserted-by":"publisher","first-page":"4015","DOI":"10.1200\/JCO.2015.62.3397","volume":"33","author":"J Hamanishi","year":"2015","unstructured":"Hamanishi, J. et al. Safety and antitumor activity of anti\u2013PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. J. Clin. Oncol. 33, 4015\u20134022 (2015).","journal-title":"J. Clin. Oncol."},{"key":"83276_CR16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamaoncol.2018.6258","volume":"5","author":"ML Disis","year":"2019","unstructured":"Disis, M. L. et al. Efficacy and safety of avelumab for patients with recurrent or refractory ovarian cancer: phase 1b results from the JAVELIN solid tumor trial. JAMA Oncol. 5, 393\u2013401 (2019).","journal-title":"JAMA Oncol."},{"key":"83276_CR17","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.ygyno.2019.05.021","volume":"154","author":"JF Liu","year":"2019","unstructured":"Liu, J. F. et al. Safety, clinical activity and biomarker assessments of atezolizumab from a Phase I study in advanced\/recurrent ovarian and uterine cancers. Gynecol. Oncol. 154, 314\u2013322 (2019).","journal-title":"Gynecol. Oncol."},{"key":"83276_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12943-016-0539-x","volume":"15","author":"Y Li","year":"2016","unstructured":"Li, Y. et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol. Cancer 15, 55 (2016).","journal-title":"Mol. Cancer"},{"key":"83276_CR19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.jaad.2017.05.047","volume":"77","author":"JM Garc\u00eda-Pedrero","year":"2017","unstructured":"Garc\u00eda-Pedrero, J. M. et al. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck. J. Am. Acad. Dermatol. 77, 527\u2013533 (2017).","journal-title":"J. Am. Acad. Dermatol."},{"key":"83276_CR20","doi-asserted-by":"publisher","first-page":"33972","DOI":"10.18632\/oncotarget.5583","volume":"6","author":"T Qin","year":"2015","unstructured":"Qin, T. et al. High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer. Oncotarget 6, 33972 (2015).","journal-title":"Oncotarget"},{"key":"83276_CR21","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.intimp.2017.08.017","volume":"52","author":"Q Wang","year":"2017","unstructured":"Wang, Q., Lou, W., Di, W. & Wu, X. Prognostic value of tumor PD-L1 expression combined with CD8+ tumor infiltrating lymphocytes in high grade serous ovarian cancer. Int. Immunopharmacol. 52, 7\u201314 (2017).","journal-title":"Int. Immunopharmacol."},{"key":"83276_CR22","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s10549-014-2988-5","volume":"146","author":"S Muenst","year":"2014","unstructured":"Muenst, S. et al. Expression of programmed death ligand 1 (PD-L1) is associated with poor prognosis in human breast cancer. Breast Cancer Res. Treat. 146, 15\u201324 (2014).","journal-title":"Breast Cancer Res. Treat."},{"key":"83276_CR23","doi-asserted-by":"publisher","first-page":"824","DOI":"10.3390\/ijms20040824","volume":"20","author":"K Pawelczyk","year":"2019","unstructured":"Pawelczyk, K. et al. Role of PD-L1 expression in non-small cell lung cancer and their prognostic significance according to clinicopathological factors and diagnostic markers. Int. J. Mol. Sci. 20, 824 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"83276_CR24","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","volume":"375","author":"M Reck","year":"2016","unstructured":"Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1\u2013positive non\u2013small-cell lung cancer. N. Engl. J. Med. 375, 1823\u20131833 (2016).","journal-title":"N. Engl. J. Med."},{"key":"83276_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-018-37186-2","volume":"9","author":"C Yuan","year":"2019","unstructured":"Yuan, C. et al. Expression of PD-1\/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters. Sci. Rep. 9, 1\u20138 (2019).","journal-title":"Sci. Rep."},{"key":"83276_CR26","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1111\/pcmr.12340","volume":"28","author":"J Madore","year":"2015","unstructured":"Madore, J. et al. PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1\/PD-L 1 clinical trials. Pigment Cell Melanoma Res. 28, 245\u2013253 (2015).","journal-title":"Pigment Cell Melanoma Res."},{"key":"83276_CR27","doi-asserted-by":"publisher","first-page":"1158","DOI":"10.1158\/2326-6066.CIR-15-0043","volume":"3","author":"M Callea","year":"2015","unstructured":"Callea, M. et al. Differential expression of PD-L1 between primary and metastatic sites in clear-cell renal cell carcinoma. Cancer Immunol. Res. 3, 1158\u20131164 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"83276_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ygyno.2016.12.021","volume":"144","author":"CE Gottlieb","year":"2017","unstructured":"Gottlieb, C. E., Mills, A. M., Cross, J. V. & Ring, K. L. Tumor-associated macrophage expression of PD-L1 in implants of high grade serous ovarian carcinoma: a comparison of matched primary and metastatic tumors. Gynecol. Oncol. 144, 607\u2013612 (2017).","journal-title":"Gynecol. Oncol."},{"key":"83276_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nature14011","volume":"515","author":"RS Herbst","year":"2014","unstructured":"Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563\u2013567 (2014).","journal-title":"Nature"},{"key":"83276_CR30","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387, 1909\u20131920 (2016).","journal-title":"Lancet"},{"key":"83276_CR31","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1200\/JCO.2016.71.9476","volume":"35","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed death-ligand 1\u2013selected advanced non-small-cell lung cancer (BIRCH). J. Clin. Oncol. 35, 2781 (2017).","journal-title":"J. Clin. Oncol."},{"key":"83276_CR32","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108\u20132121 (2018).","journal-title":"N. Engl. J. Med."},{"key":"83276_CR33","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1097\/JTO.0000000000000500","volume":"10","author":"N Chen","year":"2015","unstructured":"Chen, N. et al. Upregulation of PD-L1 by EGFR activation mediates the immune escape in EGFR-driven NSCLC: implication for optional immune targeted therapy for NSCLC patients with EGFR mutation. J. Thorac. Oncol. 10, 910\u2013923 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"83276_CR34","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1038\/bjc.2015.101","volume":"112","author":"K Abiko","year":"2015","unstructured":"Abiko, K. et al. IFN-\u03b3 from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. Br. J. Cancer 112, 1501\u20131509 (2015).","journal-title":"Br. J. Cancer"},{"key":"83276_CR35","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1186\/1479-5876-12-151","volume":"12","author":"D Quandt","year":"2014","unstructured":"Quandt, D., Jasinski-Bergner, S., M\u00fcller, U., Schulze, B. & Seliger, B. Synergistic effects of IL-4 and TNF\u03b1 on the induction of B7\u2013H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation. J. Transl. Med. 12, 151 (2014).","journal-title":"J. Transl. Med."},{"key":"83276_CR36","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1073\/pnas.0611533104","volume":"104","author":"J Hamanishi","year":"2007","unstructured":"Hamanishi, J. et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. 104, 3360\u20133365 (2007).","journal-title":"Proc. Natl. Acad. Sci."},{"key":"83276_CR37","doi-asserted-by":"crossref","unstructured":"Zhu, J., Wen, H., Bi, R., Wu, Y. & Wu, X. Prognostic value of programmed death-ligand 1 (PD-L1) expression in ovarian clear cell carcinoma. J. Gynecol. Oncol. 28 (2017).","DOI":"10.3802\/jgo.2017.28.e77"},{"key":"83276_CR38","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ygyno.2016.03.008","volume":"141","author":"JR Webb","year":"2016","unstructured":"Webb, J. R., Milne, K., Kroeger, D. R. & Nelson, B. H. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 141, 293\u2013302 (2016).","journal-title":"Gynecol. Oncol."},{"key":"83276_CR39","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1093\/annonc\/mdw625","volume":"28","author":"S Mesnage","year":"2017","unstructured":"Mesnage, S. et al. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC). Ann. Oncol. 28, 651\u2013657 (2017).","journal-title":"Ann. Oncol."},{"key":"83276_CR40","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1016\/j.ygyno.2018.08.023","volume":"151","author":"H-S Kim","year":"2018","unstructured":"Kim, H.-S. et al. Expression of programmed cell death ligand 1 and immune checkpoint markers in residual tumors after neoadjuvant chemotherapy for advanced high-grade serous ovarian cancer. Gynecol. Oncol. 151, 414\u2013421 (2018).","journal-title":"Gynecol. Oncol."},{"key":"83276_CR41","doi-asserted-by":"crossref","unstructured":"Huang, L.-J. et al. Prognostic significance of programmed cell death ligand 1 expression in patients with ovarian carcinoma: a systematic review and meta-analysis. Medicine 97 (2018).","DOI":"10.1097\/MD.0000000000012858"},{"key":"83276_CR42","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.18632\/oncotarget.6429","volume":"7","author":"S Darb-Esfahani","year":"2016","unstructured":"Darb-Esfahani, S. et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma. Oncotarget 7, 1486 (2016).","journal-title":"Oncotarget"},{"key":"83276_CR43","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s10147-016-0968-y","volume":"21","author":"M Mandai","year":"2016","unstructured":"Mandai, M. et al. Anti-PD-L1\/PD-1 immune therapies in ovarian cancer: basic mechanism and future clinical application. Int. J. Clin. Oncol. 21, 456\u2013461 (2016).","journal-title":"Int. J. Clin. Oncol."},{"key":"83276_CR44","unstructured":"Zhu, H. & Zhang, R. (AME Publ Co Room 604 6-F Hollywood Center, 77\u201391, QUEENS Road, Sheung Wan\u00a0\u2026, 2017)."},{"key":"83276_CR45","doi-asserted-by":"publisher","first-page":"2885","DOI":"10.1038\/s41388-018-0637-x","volume":"38","author":"T Motohara","year":"2019","unstructured":"Motohara, T. et al. An evolving story of the metastatic voyage of ovarian cancer cells: cellular and molecular orchestration of the adipose-rich metastatic microenvironment. Oncogene 38, 2885\u20132898 (2019).","journal-title":"Oncogene"},{"key":"83276_CR46","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ygyno.2014.04.013","volume":"133","author":"DG Mutch","year":"2014","unstructured":"Mutch, D. G. & Prat, J. 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer. Gynecol. Oncol. 133, 401\u2013404 (2014).","journal-title":"Gynecol. Oncol."},{"key":"83276_CR47","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2214\/AJR.15.15199","volume":"206","author":"S Javadi","year":"2016","unstructured":"Javadi, S., Ganeshan, D. M., Qayyum, A., Iyer, R. B. & Bhosale, P. Ovarian cancer, the revised FIGO staging system, and the role of imaging. Am. J. Roentgenol. 206, 1351\u20131360 (2016).","journal-title":"Am. J. Roentgenol."},{"key":"83276_CR48","doi-asserted-by":"publisher","first-page":"e1277308","DOI":"10.1080\/2162402X.2016.1277308","volume":"6","author":"BE Howitt","year":"2017","unstructured":"Howitt, B. E. et al. Clear cell ovarian cancers with microsatellite instability: a unique subset of ovarian cancers with increased tumor-infiltrating lymphocytes and PD-1\/PD-L1 expression. Oncoimmunology 6, e1277308 (2017).","journal-title":"Oncoimmunology"},{"key":"83276_CR49","doi-asserted-by":"publisher","first-page":"3753","DOI":"10.1158\/1078-0432.CCR-18-4070","volume":"25","author":"L Marcus","year":"2019","unstructured":"Marcus, L., Lemery, S. J., Keegan, P. & Pazdur, R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin. Cancer Res. 25, 3753\u20133758 (2019).","journal-title":"Clin. Cancer Res."},{"key":"83276_CR50","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/PAS.0000000000000298","volume":"38","author":"MH Chui","year":"2014","unstructured":"Chui, M. H. et al. The histomorphology of Lynch syndrome\u2013associated ovarian carcinomas: toward a subtype-specific screening strategy. Am. J. Surg. Pathol. 38, 1173\u20131181 (2014).","journal-title":"Am. J. Surg. Pathol."},{"key":"83276_CR51","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/path.2215","volume":"213","author":"A Siraj","year":"2007","unstructured":"Siraj, A. et al. Genome-wide expression analysis of Middle Eastern papillary thyroid cancer reveals c-MET as a novel target for cancer therapy. J. Pathol. 213, 190\u2013199 (2007).","journal-title":"J. Pathol."},{"key":"83276_CR52","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1158\/1055-9965.EPI-05-0972","volume":"15","author":"P Bavi","year":"2006","unstructured":"Bavi, P. et al. Prevalence of fragile histidine triad expression in tumors from saudi arabia: a tissue microarray analysis. Cancer Epidemiol. Prev. Biomark. 15, 1708\u20131718 (2006).","journal-title":"Cancer Epidemiol. Prev. Biomark."},{"key":"83276_CR53","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1002\/cncr.29288","volume":"121","author":"AK Siraj","year":"2015","unstructured":"Siraj, A. K. et al. Prevalence of Lynch syndrome in a Middle Eastern population with colorectal cancer. Cancer 121, 1762\u20131771 (2015).","journal-title":"Cancer"},{"key":"83276_CR54","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1007\/s10549-015-3430-3","volume":"151","author":"S Beg","year":"2015","unstructured":"Beg, S. et al. Loss of PTEN expression is associated with aggressive behavior and poor prognosis in Middle Eastern triple-negative breast cancer. Breast Cancer Res. Treat. 151, 541\u2013553 (2015).","journal-title":"Breast Cancer Res. Treat."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83276-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83276-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83276-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T03:06:18Z","timestamp":1697857578000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-83276-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,12]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["83276"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-83276-z","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,12]]},"assertion":[{"value":"27 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3750"}}